Stockreport

Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States

FRESENIUS SE S/ADR  (FSNUY) 
NASDAQ:AMEX Investor Relations: fresenius.com/index
PDF Tyenne® is the first tocilizumab biosimilar available with both an intravenous and subcutaneous formulation approved by the FDA.The subcutaneous formulation of the tocil [Read more]